F
Fernando Rivera
Researcher at Cuatrecasas
Publications - 27
Citations - 9094
Fernando Rivera is an academic researcher from Cuatrecasas. The author has contributed to research in topics: Oxaliplatin & Genome-wide association study. The author has an hindex of 16, co-authored 27 publications receiving 8302 citations.
Papers
More filters
Journal ArticleDOI
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken,Ricard Mesia,Fernando Rivera,Eva Remenar,Andrzej Kawecki,Sylvie Rottey,Jozsef Erfan,Dmytro Zabolotnyy,Heinz Roland Kienzer,Didier Cupissol,Frederic Peyrade,Marco Benasso,Ihor Vynnychenko,Dominique De Raucourt,Carsten Bokemeyer,Armin Schueler,Nadia Amellal,Ricardo Hitt +17 more
TL;DR: Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracils) significantly prolonged the median overall survival and improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Leonard B. Saltz,Stephen Clarke,Eduardo Díaz-Rubio,Werner Scheithauer,Arie Figer,Ralph Wong,Sheryl Koski,Mikhail Lichinitser,T. Yang,Fernando Rivera,Félix Couture,Florin Sirzen,Jim Cassidy +12 more
TL;DR: The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS in this first-line trial in patients with MCRC.
Journal ArticleDOI
Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
Jim Cassidy,Stephen Clarke,Eduardo Díaz-Rubio,Werner Scheithauer,Arie Figer,Ralph Wong,Sheryl Koski,Mikhail Lichinitser,T. Yang,Fernando Rivera,Félix Couture,Florin Sirzen,Leonard B. Saltz +12 more
TL;DR: XELOX is noninferior to FOLFOX-4 as a first-line treatment for MCRC, and may be considered as a routine treatment option for appropriate patients, according to the results of the analysis of the XELOX versus FOL FOX-4 arms.
Journal ArticleDOI
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
Christophe Tournigand,Andrés Cervantes,Arie Figer,Gérard Lledo,M. Flesch,Marc Buyse,Laurent Mineur,Elisabeth Carola,Pierre-Luc Etienne,Fernando Rivera,Isabel Chirivella,N. Perez-Staub,Christophe Louvet,Thierry André,Isabelle Tabah-Fisch,Aimery de Gramont +15 more
TL;DR: Oxaliplatin can be safely stopped after six cycles in a FOLFOX regimen, and further study is needed to fully evaluate oxali Platin reintroduction.
Journal ArticleDOI
Mutations in BRIP1 confer high risk of ovarian cancer
Thorunn Rafnar,Daniel F. Gudbjartsson,Patrick Sulem,Aslaug Jonasdottir,Asgeir Sigurdsson,Adalbjorg Jonasdottir,Søren Besenbacher,Pär Lundin,Simon N. Stacey,Julius Gudmundsson,Olafur T. Magnusson,Louise le Roux,Gudbjorg Orlygsdottir,Hafdis T. Helgadottir,Hrefna Johannsdottir,Arnaldur Gylfason,Laufey Tryggvadottir,Jon G. Jonasson,Ana de Juan,Eugenia Ortega,Jose M. Ramon-Cajal,Maria D. Garcia-Prats,Carlos Mayordomo,Angeles Panadero,Fernando Rivera,Katja K.H. Aben,Anne M. van Altena,Leon F.A.G. Massuger,Mervi Aavikko,Paula Kujala,Synnöve Staff,Lauri A. Aaltonen,Kristrun Olafsdottir,Johannes Bjornsson,Augustine Kong,Anna Salvarsdottir,Hafsteinn Saemundsson,Karl Olafsson,Kristrun R. Benediktsdottir,Jeffrey R. Gulcher,Gisli Masson,Lambertus A. Kiemeney,Jose I. Mayordomo,Unnur Thorsteinsdottir,Unnur Thorsteinsdottir,Kari Stefansson,Kari Stefansson +46 more
TL;DR: Ovarian tumors from heterozygous carriers of the Icelandic mutation show loss of the wild-type allele, indicating that BRIP1 behaves like a classical tumor suppressor gene in ovarian cancer.